Independent lab data for grey market peptides
Research peptide vendors, rated by real lab tests
Buying tirzepatide, retatrutide or other research peptides on the grey market? See how 67 vendors did when their vials went to independent labs like Janoshik: purity, dose vs. label, and how often vials fail.
- vials tested
- 1,754
- lab reports
- 1,009
- of vials failed
- 3.9%
- newest result
- Oct 2026
A vial fails if it's empty, under 95% pure, more than 20% under its label, or more than 50% over. 69 of 1,751 vials failed. A lab report is one test certificate and can cover several vials.
Have a lab report for a vial you bought? Submit it
Every vial on file, against its label
One dot per vial, placed by how much it held compared with the amount on the label.
Dot chart of 1,653 vials (every vial on file), each placed by its measured amount compared with the label, from 50% under to 50% over. 545 are within 5% of the label, 1,053 are 5 to 20% under or more than 5% over, 44 are more than 20% under or more than 50% over, and 11 were empty.
83% of vials held more than the label and 17% held less. The ones to worry about sit on the left.
Top vendors for Tirzepatide
| Vendor | Verdict | Score | Failed vials | Lab reports | Median dose vs label | Avg. purity | Vendor page |
|---|---|---|---|---|---|---|---|
| BFF/AMO | Above market | 95.7 | 1.2% | 118 | +2.5% | 99.63% | View vendor BFF/AMO |
| SSA | Above market | 92.5 | 1.1% | 46 | +6.6% | 99.47% | View vendor SSA |
| TCI | Above market | 92.1 | 0.0% | 28 | +9.3% | 99.76% | View vendor TCI |
| ASC | Above market | 91.7 | 0.0% | 16 | +4.2% | 99.60% | View vendor ASC |
| FSD | Above market | 91.4 | 0.0% | 10 | +5.0% | 99.70% | View vendor FSD |
| SPB | Above market | 90.6 | 0.0% | 6 | +8.5% | 99.85% | View vendor SPB |
| SRY | Above market | 90.0 | 1.9% | 68 | +9.0% | 99.50% | View vendor SRY |
| APS | Above market | 90.0 | 0.0% | 7 | +11.6% | 99.65% | View vendor APS |
| YC | At market | 89.3 | 0.0% | 6 | +7.0% | 99.37% | View vendor YC |
| ALM | At market | 89.1 | 0.0% | 6 | +7.8% | 99.63% | View vendor ALM |
| Uther | At market | 89.0 | 0.0% | 9 | +10.6% | 99.86% | View vendor Uther |
| ACR | At market | 88.3 | 0.0% | 10 | +9.5% | 99.68% | View vendor ACR |
| GYC | At market | 87.8 | 4.5% | 20 | +9.5% | 99.69% | View vendor GYC |
| PGB | At market | 87.8 | 0.0% | 5 | +16.3% | 99.76% | View vendor PGB |
| SNP | At market | 83.7 | 3.8% | 26 | +18.0% | 99.57% | View vendor SNP |
| JEC | Below marketFailed vials | 80.0 | 20.0% | 5 | +15.8% | 99.90% | View vendor JEC |
| Not enough data to rank (fewer than 5 lab reports) | |||||||
| QSC | Not ranked | 89.1 | 0.0% | 4 | +7.6% | 99.52% | View vendor QSC |
| LSPL | Not ranked | 88.8 | 0.0% | 3 | +2.9% | 99.56% | View vendor LSPL |
| BDB | Not ranked | 88.2 | 0.0% | 4 | +15.9% | 99.79% | View vendor BDB |
| ABC | Not ranked | 87.8 | 0.0% | 3 | +11.6% | 98.85% | View vendor ABC |
| QST | Not ranked | 87.8 | 0.0% | 2 | +6.9% | 99.71% | View vendor QST |
How scores work
Purity
HPLC purity of each vial. Differences above 99.5% are within normal lab-to-lab variation, so they aren't rewarded.
Dose vs label
How close the measured amount is to the label. Coming in under the label costs more than modest overfill.
Failure rate
How often vials fail outright: empty, under 95% pure, more than 20% under the label or more than 50% over.
Consistency
How steady purity and dose are from one lab report to the next.